NeoVac names Jan Hendrik Egberts as chief executive officer

NeoVac has appointed Jan Hendrik Egberts as chief executive officer to steer the company’s next stage of growth. The Oxfordshire-based biotech, which focuses on lipid nanoparticle (LNP) technologies for RNA medicines, said the leadership change comes as it shifts from platform validation to scale-up.

Dr Egberts, who has more than 25 years of industry experience, has previously served as chief executive, board chair and investor across both public and private healthcare companies. Most recently, he led Veritas Investment, his family office holding eight medical technology businesses in Europe, while maintaining minority stakes in more than 10 private firms. He has also held leadership roles at OctoPlus, Agendia, ViroClinics and Photocure.

The new chief executive was among NeoVac’s early investors and said he remains committed to advancing its vision for transforming RNA delivery. He will work closely with the existing management team to accelerate clinical development and broaden access to its platform.